Journal of Medicinal Chemistry · 2018 · 78 citations · 40 references
MedicineMedicinal ChemistryPharmacologyCancer PharmacologyDrug DiscoveryMolecular OncologyEnzyme InhibitionHit-to-lead OptimizationOncology PharmacologyStructure-activity Relationship AnalysisAnticancer ActivityCancer Cell ApoptosisCell Death In CancerCyclin-dependent Kinase 4 InhibitorsCyclin-dependent Kinase 4/6 InhibitorsKinase Inhibitor Library DesignSelective Cancer Therapy
A series of novel, highly potent, selective inhibitors targeting both CDK4/9 and HDAC1 have been designed and synthesized. N1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7H-pyrrolo[2,3-d] pyrimidin-2-yl)amino)phenyl)-N8-hydroxyoctanediamide (6e) was discovered. The lead compound 6e with excellent CDK4/9 and HDAC1 inhibitory activity of IC50 = 8.8, 12, and 2.2 nM, respectively, can effectively induce apoptosis of cancer cell lines. The kinase profiling of compound 6e showed excellent selectivity and specificity. Compound 6e induces G2/M arrest in high concentration and G0/G1 arrest in low concentration to prevent the proliferation and differentiation of cancer cells. Mice bared-breast cancer treated with 6e showed significant antitumor efficacy. The insight into mechanisms of 6e indicated that it could induce cancer cell death via cell apoptosis based on CDK4/9 and HDAC1 repression and phosphorylation of p53. Our data demonstrated the novel compound 6e could be a promising drug candidate for cancer therapy.
40
The PyMOL Molecular Graphics System
Warren L. DeLano · Medical Entomology and Zoology · 2002 · 18.1K citations
Protein Structure Modeling with MODELLER
Narayanan Eswar, David Eramian, Ben Webb et al. · Methods in molecular biology · 2008 · 1.8K citations
Richard S. Finn, Judy Dering, Dylan Conklin et al. · Breast Cancer Research · 2009 · 1.4K citations · Full text
Medicine, Oncology, Pharmacology +17